Scientists Re-Engineer Patient's own cells to hunt down HPV cancers
NCT ID NCT02858310
Summary
This trial tested a new type of treatment for cancers caused by HPV-16, including cervical, throat, and anal cancers. Doctors took a patient's own immune cells, genetically modified them in a lab to better recognize and attack cancer cells, and then infused them back into the patient. The goal was to find a safe dose and see if this personalized cell therapy could shrink tumors in people with advanced HPV-related cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PAPILLOMAVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
-
Rutgers Cancer Institute of New Jersey
New Brunswick, New Jersey, 08901, United States
Conditions
Explore the condition pages connected to this study.